Enzon Pharmaceuticals, Inc. (ENZN)

OTCMKTS · Delayed Price · Currency is USD
0.0856
+0.0059 (7.40%)
Aug 26, 2025, 1:27 PM EDT
7.40%
Market Cap5.91M
Revenue (ttm)n/a
Net Income (ttm)-2.61M
Shares Out74.21M
EPS (ttm)-0.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume23,676
Average Volume33,338
Open0.0855
Previous Close0.0797
Day's Range0.0830 - 0.0878
52-Week Range0.0555 - 0.2350
Beta0.30
RSI48.16
Earnings DateAug 8, 2025

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the sale of its patented drug product, PegIntron. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1981
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol ENZN
Full Company Profile

Financial Performance

Financial Statements

News

Enzon and Viskase Enter into Merger Agreement

Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined company Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the com...

2 months ago - GlobeNewsWire

Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO

CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Com...

5 years ago - GlobeNewsWire

Enzon Pharmaceuticals Announces Results of Rights Offering

Looking to Next Step – Acquisition Opportunities Looking to Next Step – Acquisition Opportunities

5 years ago - GlobeNewsWire

Enzon Pharmaceuticals Announces Key Dates for Rights Offering

CRANFORD, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its previous...

5 years ago - GlobeNewsWire

Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting

CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual Meeting...

5 years ago - GlobeNewsWire

Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders

CRANFORD, N.J., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved a rights o...

5 years ago - GlobeNewsWire

Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value

CRANFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax benefits p...

5 years ago - GlobeNewsWire

Bullish On Enzon And Sesen From Different Perspectives

ENZN trades at all time highs, adjusted for dividends, and double the "base case" of the liquidation value.

6 years ago - Seeking Alpha

Enzon Pharmaceuticals - Heads Equals Royalties, Tails Equals Cash

Trading for less than its liquid book value.

6 years ago - Seeking Alpha